The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: International external validation and site-specific recalibration in two independent European samples
Abstract
Background Cardiometabolic dysfunction is common in young people with psychosis. Recently, the Psychosis Met-abolic Risk Calculator (PsyMetRiC) was developed and externally validated in the UK, predicting up-to six-year risk of metabolic syndrome (MetS) from routinely collected data.
The full-model includes age, sex, ethnicity, body-mass index, smoking status, prescription of metabolically-active antipsychotic medication, high-density lipoprotein, and triglyceride concentrations; the partial-model excludes biochemical predictors. Methods To move toward a future internationally-useful tool, we externally validated PsyMetRiC in two independent European samples.
We used data from the PsyMetab (Lausanne, Switzerland) and PAFIP (Cantabria, Spain) cohorts, including participants aged 16-35y without MetS at baseline who had 1-6y follow-up. Predictive performance was assessed primarily via discrimination (C-statistic), calibration (calibration plots), and decision curve analysis.
Site -specific recalibration was considered. Findings We included 1024 participants (PsyMetab n=558, male=62%, outcome prevalence=19%, mean follow-up=2.48y; PAFIP n=466, male=65%, outcome prevalence=14%, mean follow-up=2.59y).
Discrimination was better in the full-compared with partial-model (PsyMetab=full-model C=0.73, 95% C.I., 0.68-0.79, partial-model C=0.68, 95% C.I., 0.62-0.74; PAFIP=full-model C=0.72, 95% C.I., 0.66-0.78; partial-model C=0.66, 95% C.I., 0.60-0.71). As expected, calibration plots revealed varying degrees of miscalibration, which recovered following site-specific recalibration.
PsyMetRiC showed net benefit in both new cohorts, more so after recalibration. Interpretation The study provides evidence of PsyMetRiC's generalizability in Western Europe, although further local and international validation studies are required.
In future, PsyMetRiC could help clinicians internationally to identify young people with psychosis who are at higher cardiometabolic risk, so interventions can be directed effec-tively to reduce long-term morbidity and mortality.For the Spanish and French translation of the abstract see Supplementary Materials section.Copyright (c) 2022 The Author(s). Published by Elsevier Ltd.